Yu et al. [36] reported that LOXL1 functions as an important mediator that increases the antiapoptotic capacity of tumour cells, suggesting that targeting LOXL1 could be a potential strategy for treating glioma. This evidence concerns the gene LOXL1 and central nervous system cancer.